Home › Funds › Medicxi Ventures Management (Jersey) Ltd › PHAT
Medicxi Ventures Management (Jersey) Ltd position in PHAT
PHATHOM PHARMACEUTICALS INC · Health Care
Medicxi Ventures Management (Jersey) Ltd reported holding 7,464,572 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$54.5M, representing 43.02% of its reported portfolio and ranking #1 among its reported holdings. Medicxi Ventures Management (Jersey) Ltd has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Medicxi Ventures Management (Jersey) Ltd's PHAT position evolved
Medicxi Ventures Management (Jersey) Ltd first disclosed a stake in PHAT in Q3 2023 at 3,760,869 shares (US$39.0M). The position peaked in Q3 2024 at 7,464,572 shares, worth US$135.0M. Across 13 filings, Medicxi Ventures Management (Jersey) Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 7,464,572 shares valued at US$54.5M. Notable position changes include a 98% increase in Q1 2024 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.76M | $39.00M | New |
| Q4 2023 | 3.76M | $34.34M | Hold |
| Q1 2024 | 7.46M | $79.27M | Add |
| Q2 2024 | 7.46M | $76.89M | Hold |
| Q3 2024 | 7.46M | $134.96M | Hold |
| Q4 2024 | 7.46M | $60.61M | Hold |
| Q1 2025 | 7.46M | $46.80M | Hold |
| Q2 2025 | 7.46M | $71.59M | Hold |
| Q3 2025 | 7.46M | $87.86M | Hold |
| Q4 2025 | 7.46M | $123.84M | Hold |
| Q1 2026 | 7.46M | $82.93M | Hold |
| Q2 2026 | 7.46M | $80.99M | Hold |
| Q3 2026 | 7.46M | $54.49M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHAT and 13F data
PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Carlyle Group Inc. (US$25.5M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHAT
- Frazier Life Sciences Management, L.P. 12.47M sh · $135.26M · Q2 2026
- Carlyle Group Inc. 3.50M sh · $25.53M · Q3 2026
- NEA Management Company, LLC 1.96M sh · $21.27M · Q2 2026
- 683 Capital Management, LLC 1.85M sh · $20.07M · Q2 2026
- Catalys Pacific, LLC 1.88M sh · $13.74M · Q3 2026
- Propel Bio Management, LLC 1.11M sh · $8.07M · Q3 2026
- EcoR1 Capital, LLC 625.00K sh · $6.78M · Q2 2026
More on Medicxi Ventures Management (Jersey) Ltd
FAQ
How long has Medicxi Ventures Management (Jersey) Ltd held PHAT?
Medicxi Ventures Management (Jersey) Ltd has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Medicxi Ventures Management (Jersey) Ltd's current position in PHAT?
As of Q3 2026, Medicxi Ventures Management (Jersey) Ltd holds 7.46M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $54.49M, representing 43.02% of its reported portfolio and ranking #1.
Has Medicxi Ventures Management (Jersey) Ltd been buying or selling PHAT?
In the latest 13F filing (Q3 2026), Medicxi Ventures Management (Jersey) Ltd held unchanged its position in PHAT. The position peaked in Q3 2024 at 7.46M shares.
Which other funds hold PHAT?
Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Carlyle Group Inc., NEA Management Company, LLC, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.